Spring Bayou
Distribution Co.
Parent company of Superstratum Labs
The category creator of home detoxification — solving the root cause of mold illness.
The Problem: A National Health Crisis is Hiding in Plain Sight.
Building Related Illness (BRI) — per the EPA, an illness in which identifiable clinical signs and symptoms (such as respiratory infection, asthma, or hypersensitivity pneumonitis) can be attributed to specific airborne building contaminants.
The military is discovering what is driving chronic illness and the mental health crisis in their ranks.
There has been no category or company committed to solving the root cause of BRI.
Here's how we're solving BRI: healing the home.
Home detoxification sits between mold remediation (an insufficient building solution) and chronic-illness care (which doesn't address the root cause).
The Whole Home Detox is our proprietary system to solve mold and toxins in the home — and it's DIY, direct to the consumer.
We've built a category ecosystem.
Our moat: proprietary technology, EPA-registered claims against toxic black mold, vertical manufacturing, and brand awareness.
An enormous emerging category with no direct competitor.
We start with the people and homes actually affected — then apply our own blended LTV of $220 per customer as the per-household value.
Bottom-up sizing anchored on our own economics, not category proxies. TAM applies our $220 blended LTV to the population estimate (70M Americans affected); SAM applies the same $220 value directly at the household level (~62M households). Because TAM is sized on individuals rather than households, it should be read as a ceiling estimate rather than a precise household count. Blended LTV lifts as the repeat-purchase rate (currently 24%) climbs.
Lean team. Building with AI. Defining a category.
Running a $2.3M run-rate business — ready to scale with fuel, not headcount.
We have found product-market fit. We are a working business.
Up 58% H1'26 vs H1'25. Media efficiency improving roughly 3× year-over-year.
The equation is healthy — revenue spreads the fixed base
Every incremental revenue dollar keeps 37¢ after variable costs and marketing. Fixed costs don't grow with revenue — so profit scales.
We are expanding globally.
B2B already outperforms DTC on a per-account basis — before any dedicated investment.
With $600K we reset working capital and self-fund to $10M and beyond.
Post-PMF at $2.3M run-rate with a negative cash-conversion cycle — every incremental dollar of revenue funds the next one.